Print PDF
Axinn Represents Thermo Fisher in $7.2 Billion Acquisition of Patheon
May 17, 2017

Axinn is representing Thermo Fisher Scientific Inc. in its $7.2 billion acquisition of Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors.  The Axinn team consists of John Harkrider and Mark Alexander.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.